SUBSCRIBERS
Amgen's new cancer drug treatment to cost US$178,000
Add BT as a preferred sourcePublished Mon, Dec 22, 2014 · 09:50 PM
DeeperDive is a beta AI feature. Refer to full articles for the facts.
San Francisco
AMGEN Inc's leukaemia drug Blincyto will cost US$178,000 for a standard course of treatment, continuing a trend of high prices for immunotherapy, the newest wave of cancer treatments.
The price includes two US$89,000 cycles of therapy, the median duration of treatment for patients who responded in clinical studies, said Danielle Bertrand, a spokeswoman for Amgen, the second-biggest US biotechnology company. Each cycle consists of four weeks of treatment.
Share with us your feedback on BT's products and services
